Innovative Advisory Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.58M Buy
16,357
+9,359
+134% +$1.48M 1.88% 12
2026
Q2
$1.11M Buy
+6,998
New +$946K 0.84% 13
2026
Q1
– Sell
-21,787
Closed -$2.66M – 234
2025
Q4
$2.66M Buy
+21,787
New +$2.5M 1.69% 14

Other funds holding XBI

Innovative Advisory Group's XBI Position: Q3 2026 in Review

Innovative Advisory Group increased its State Street SPDR S&P Biotech ETF (XBI) stake by 134% in Q3 2026, buying an estimated $1.48M and bringing the position to 16,357 shares worth $2.58M. The position accounts for 1.88% of the portfolio, ranked #12.

Innovative Advisory Group first reported a position in XBI in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.66M in Q4 2025. 964 funds tracked by Wall St. Rank hold XBI as of Q3 2026.

  • Innovative Advisory Group held 16,357 shares of State Street SPDR S&P Biotech ETF worth $2.58M as of Q3 2026.
  • Innovative Advisory Group bought 9,359 State Street SPDR S&P Biotech ETF shares in Q3 2026, an estimated $1.48M.
  • State Street SPDR S&P Biotech ETF made up 1.88% of Innovative Advisory Group's portfolio in Q3 2026, its #12 holding.
  • Innovative Advisory Group first reported a position in State Street SPDR S&P Biotech ETF in Q4 2025 and has held it in 3 quarters since.
  • Innovative Advisory Group's State Street SPDR S&P Biotech ETF position peaked at $2.66M in Q4 2025.
  • 964 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2026.

Based on Innovative Advisory Group's 13F filing for Q3 2026, filed 13 Oct 2026.